Electromed Inc. Reports 13.1% Increase in Q3 Revenue and 26.7% Rise in Net Income, EPS Up to $0.21

Reuters
05-14
<a href="https://laohu8.com/S/ELMD">Electromed</a> Inc. Reports 13.1% Increase in Q3 Revenue and 26.7% Rise in Net Income, EPS Up to $0.21

Electromed, Inc. has announced its financial results for the third quarter of fiscal year 2025, showing a strong performance marked by growth in key financial metrics. The company's net revenue increased by 13.1% to $15.7 million, compared to $13.9 million in the same quarter of the previous fiscal year. This growth was significantly driven by a 14.8% year-over-year increase in revenue from the direct homecare business, which achieved $14.1 million, up from $12.3 million. The rise in revenues was attributed to more referrals and approvals, improved sales force efficiency, and increased net revenues per approval. Operating income for the quarter rose to $2.1 million, marking a 16.2% increase from the previous year's third quarter. Net income also saw a substantial rise of 26.7%, reaching $1.9 million, or $0.21 per diluted share, compared to $1.5 million, or $0.17 per diluted share, in the prior year. Additionally, Electromed's board of directors approved a $5 million stock repurchase authorization during this quarter. The company also reported an increase in operating cash flow, which reached $7.5 million for the nine months ending in the third quarter of fiscal year 2025, up by $3.0 million from the same period last year. As of March 31, 2025, Electromed had $15.2 million in cash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Electromed Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513753200) on May 13, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10